NCT00903656View on ClinicalTrials.gov

Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy

PHASE2TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Metastatic Breast Cancer
Interventions
DRUG

doxorubicinhydrochloride, Lapatinib

Lapatinib 1250mg/d p.o. Caelyx 40 mg/m² i.v. q4w for a maximum of 6 cycles

Trial Locations (1)

5020

Uniklinik Salzburg, Salzburg

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Arbeitsgemeinschaft medikamentoese Tumortherapie

OTHER

NCT00903656 - Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy | Biotech Hunter | Biotech Hunter